Abstract
2371P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have